The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.
B. Jimenez
No relevant relationships to disclose
J. M. Trigo Perez
No relevant relationships to disclose
M. I. Saez Medina
No relevant relationships to disclose
C. Quero Blanco
No relevant relationships to disclose
B. Pajares
No relevant relationships to disclose
A. Rueda
No relevant relationships to disclose
E. Alba
No relevant relationships to disclose